WOMENS ISCHEMIC SYNDROME EVALUATION

这项由NHLBI赞助的多中心调查正在寻求更准确的 女性心肌缺血的诊断方法。这是公认的 所有可用于评估缺血的方法(病史、心电图、 运动、跑步机、ECHO和核成像)对女性的可靠性较低 而不是男人。女性缺血性综合征评估(WISE)正在检查 在四个医疗中心评估缺血的创新技术- 阿拉巴马大学伯明翰分校、佛罗里达大学、 匹兹堡和阿勒格尼综合医院。在UAB，创新的 这项技术包括心脏的磁共振成像，在 休息，然后静脉注射潘生丁。所有患者均接受冠状动脉 动脉造影术用于临床常见指征，也可用于静脉注射 潘生丁。所有患者均按常规进行冠状动脉造影术。 适应症，并接受常规核素灌注成像 学习。其他中心正在评估核磁共振冠状动脉造影术，正电子 发射断层扫描(PET)，冠状动脉内血管活性注射，以及 多巴酚丁胺回声。

This multicenter NHLBI-sponsored inveestigation is seeking more accurate methods for diagnosing myocardial ischemia in women. It is recognized that all of the available modalities for assessing ischemia (history, ECG, exercise treadmill, echo and nuclear imaging) are less reliable in women than men. Women's Ischemic Syndrome Evaluation (WISE) is examining innovative technology for assessing ischemia at four medical centers - University of Alabama at Birmingham, University of Florida, University of Pittsburgh and Allegheny General Hospital. At UAB the innovative technology consists of magnetic resonance imaging of the heart both at rest and following intravenous persantine. All patients undergo coronary arteriography for usual clinical indications and also intravenous persantine. All patients undergo coronary arteriography for usual clinical indications and also receive a conventional radionuclide perfusion imaging study. Other centers are evaluating MRI coronary arteriography, positron emission tomography (PET), intracoronary vasoactive infuions, and dobutamine echo.